Q1 EPS Forecast for OnKure Therapeutics Reduced by Analyst

OnKure Therapeutics (NASDAQ:OKUR) – Equities research analysts at HC Wainwright dropped their Q1 2025 earnings per share (EPS) estimates for shares of OnKure Therapeutics in a research note issued on Tuesday, March 18th. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($1.41) per share for the quarter, down from their prior estimate of ($1.19). HC Wainwright currently has a “Buy” rating and a $34.00 price target on the stock. The consensus estimate for OnKure Therapeutics’ current full-year earnings is ($4.05) per share. HC Wainwright also issued estimates for OnKure Therapeutics’ Q2 2025 earnings at ($1.43) EPS, Q3 2025 earnings at ($1.27) EPS, Q4 2025 earnings at ($1.15) EPS and FY2025 earnings at ($5.20) EPS.

OnKure Therapeutics (NASDAQ:OKUR) last announced its quarterly earnings results on Monday, March 10th. The company reported ($1.37) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.51).

Other equities research analysts have also issued research reports about the company. Oppenheimer dropped their price target on OnKure Therapeutics from $35.00 to $30.00 and set an “outperform” rating for the company in a research note on Tuesday, March 11th. Leerink Partners began coverage on OnKure Therapeutics in a research report on Thursday, December 5th. They issued an “outperform” rating and a $33.00 target price for the company. Finally, Leerink Partnrs upgraded shares of OnKure Therapeutics to a “strong-buy” rating in a research report on Thursday, December 5th. Three equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $32.33.

OnKure Therapeutics Trading Up 1.0 %

Shares of NASDAQ:OKUR opened at $5.05 on Thursday. The company’s 50 day moving average price is $5.44. The stock has a market capitalization of $67.85 million, a PE ratio of -0.41 and a beta of 0.28. OnKure Therapeutics has a 12 month low of $4.45 and a 12 month high of $20.00.

Institutional Investors Weigh In On OnKure Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Vestal Point Capital LP purchased a new position in OnKure Therapeutics in the 4th quarter worth approximately $5,461,000. Two Sigma Advisers LP purchased a new position in shares of OnKure Therapeutics in the fourth quarter worth $122,000. Tang Capital Management LLC bought a new stake in OnKure Therapeutics during the 4th quarter valued at $2,534,000. Shay Capital LLC purchased a new stake in OnKure Therapeutics during the 4th quarter valued at $129,000. Finally, Sphera Funds Management LTD. bought a new stake in OnKure Therapeutics in the 4th quarter worth $751,000. Institutional investors own 90.98% of the company’s stock.

About OnKure Therapeutics

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.